Abd-Elsalam, et al. (2020) [36]  Multicenter, randomized controlled trial194 COVID-19 infected patients  HCQ group -> SOC+ HCQ (400 mg twice daily, on day 1, followed by 200 mg tablets twice daily)Control group -> SOC4 weeks of treatment  There was no significant difference between the two groups regarding any laboratory parameters or the baseline characteristics.